Overview
Wave Life Sciences is a clinical-stage biotechnology company headquartered in Lexington, Massachusetts, focused on developing transformational RNA medicines across multiple modalities including RNA editing, splicing, RNA interference, and antisense silencing. The company leverages its proprietary PRISM platform, which combines advanced oligonucleotide chemistry, sequence design, and delivery strategies to address genetic and acquired diseases spanning neurology, muscle disorders, liver disease, and metabolic conditions such as obesity. Wave's pipeline encompasses first- or best-in-class therapeutics targeting alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington's disease, and other serious genetic conditions, with the overarching mission to unlock the therapeutic potential of RNA-targeting approaches to transform human health.